Last: | $1.84 |
---|---|
Change Percent: | -2.13% |
Open: | $1.88 |
Close: | $1.88 |
High: | $1.96 |
Low: | $1.84 |
Volume: | 18,767 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.84 | $1.88 | $1.88 | $1.96 | $1.84 | 18,767 | 07-03-2024 |
$1.88 | $1.89 | $1.88 | $1.9 | $1.8 | 70,895 | 07-02-2024 |
$1.86 | $1.94 | $1.86 | $1.98 | $1.84 | 107,305 | 07-01-2024 |
$1.95 | $1.93 | $1.95 | $1.97 | $1.83 | 119,810 | 06-28-2024 |
$1.9 | $1.83 | $1.9 | $1.92 | $1.81 | 60,302 | 06-27-2024 |
$1.82 | $1.78 | $1.82 | $1.84 | $1.78 | 38,056 | 06-26-2024 |
$1.81 | $1.81 | $1.81 | $1.8699 | $1.8 | 35,707 | 06-25-2024 |
$1.82 | $1.86 | $1.82 | $1.92 | $1.81 | 75,476 | 06-24-2024 |
$1.89 | $1.84 | $1.89 | $1.96 | $1.8 | 136,480 | 06-21-2024 |
$1.88 | $2.08 | $1.88 | $2.0944 | $1.86 | 126,487 | 06-20-2024 |
$2.07 | $1.83 | $2.07 | $2.08 | $1.81 | 186,688 | 06-19-2024 |
$2.07 | $1.83 | $2.07 | $2.08 | $1.81 | 186,688 | 06-18-2024 |
$1.82 | $1.86 | $1.82 | $1.86 | $1.74 | 66,411 | 06-17-2024 |
$1.822 | $1.92 | $1.822 | $1.9461 | $1.75 | 107,772 | 06-14-2024 |
$1.94 | $1.97 | $1.94 | $2.0299 | $1.89 | 74,094 | 06-13-2024 |
$1.97 | $1.9 | $1.97 | $1.98 | $1.85 | 101,341 | 06-12-2024 |
$1.85 | $1.87 | $1.85 | $1.88 | $1.82 | 36,982 | 06-11-2024 |
$1.86 | $1.87 | $1.86 | $1.91 | $1.85 | 46,105 | 06-10-2024 |
$1.87 | $2 | $1.87 | $2.01 | $1.86 | 57,883 | 06-07-2024 |
$2.04 | $2 | $2.04 | $2.13 | $1.9612 | 134,887 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...